GrafixPL PRIME Evaluation Case Study

The University of Texas System (UT)

Status and phase: Completed; Phase 4

Conditions: Diabetic Foot Ulcer

Treatments: Biological: GrafixPL PRIME

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03742440

022018-035

Details and patient eligibility

About

The investigators plan to evaluate healing in a cohort of patients with chronic wounds (n=40) that receive optimal treatment including serial wound debridement and off-loading with total contact casts or a boot and GrafixPL PRIME. In addition, the investigators will collect data on other potential confounding factors that could affect healing such as medications, tobacco, nutrition, comorbidities, diabetes control, infection, perfusion, and activity. Wound healing, including wound size and adverse events will be evaluated. The objective of this study is to understand the use of this product to evaluate wound healing in 40 patients.

Full description

Screening and Enrollment:

• Review and sign the Informed Consent and HIPAA Authorization
• Review the inclusion and exclusion criteria

If the subject qualifies for the study, they will participate in the following procedures (weekly visits, +/-4 days):

Visit 0:

• Demographics (such as age, gender, race or ethnicity)
• Medical/Surgical and Social History, Current Antibiotics.
• Laboratory Results
• Vascular - ABI
• Neurological evaluation - Monofilament and VPT
• Vitals - Sitting blood pressure and Pulse rate, Height/Weight, and BMI
• Wound debridement
• eKare - Wound imaging measurement
• Application of GrafixPL PRIME
• Current Antibiotics
• Offloading
• Adverse Events
• Source documentation

Visits 1 - 11:

• Wound debridement
• eKare - Wound imaging measurement
• Application of GrafixPL PRIME
• Current Antibiotics
• Offloading
• Adverse Events
• Source documentation

Visit 12/End of Study (EOS) Visit:

• Wound debridement
• eKare - Wound imaging measurement
• Current Antibiotics
• Offloading
• Adverse Events
• Source documentation (End of Study will occur on the date the subject is healed)

Enrollment: 40 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Able to provide informed consent
• 18-90 years of age
• Chronic foot ulceration below the ankle - persistent for 30 days or longer
• Ankle Brachial Index (ABI) >0.5 (Bedside ABI is acceptable for screening purposes as the formal imaging ABI may not be resulted prior to surgery)

Exclusion criteria

• Unable to provide informed consent
• <18 or >90 years of age
• History of poor compliance with follow-up visits
• Gangrene
• Untreated Osteomyelitis
• Widespread malignancy
• Active alcohol or substance abuse such as cocaine, heroin, or methamphetamines
• Currently Pregnant or planning pregnancy during the course of intended participation in the study
• Is nursing or actively lactating

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

GrafixPL PRIME

Other group

Description:

Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.

Treatment:

Biological: GrafixPL PRIME